1
|
Lubis AM, Yunihastuti E, Harahap AS, Anindyah G, Yasmin A, Aisyah MR. Complete hematological response with imatinib mesylate in a corticosteroid refractory idiopathic hypereosinophilic syndrome in person living with HIV: A case report. Int J STD AIDS 2025:9564624251338593. [PMID: 40331909 DOI: 10.1177/09564624251338593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2025]
Abstract
We present a case of a 38-year-old person living with HIV (PLHIV) diagnosed with refractory idiopathic hypereosinophilic syndrome (HES). His initial symptoms were pruritic skin rash, dry cough, and diarrhea. The patient was unresponsive to corticosteroid as a first-line therapy. Subsequent treatment with Imatinib mesylate 100 mg per day resulted in excellent and sustained hematological and clinical response, with a likely molecular response as well.
Collapse
Affiliation(s)
- Anna Mira Lubis
- Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
| | - Evy Yunihastuti
- Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
- HIV Integrated Unit, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
| | - Agnes Stephanie Harahap
- Department of Anatomical Pathology, Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
| | | | - Amirah Yasmin
- Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
| | - Matdoan Rifkiah Aisyah
- Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
| |
Collapse
|
2
|
Gazzinelli-Guimaraes PH, Jones SM, Voehringer D, Mayer-Barber KD, Samarasinghe AE. Eosinophils as modulators of host defense during parasitic, fungal, bacterial, and viral infections. J Leukoc Biol 2024; 116:1301-1323. [PMID: 39136237 DOI: 10.1093/jleuko/qiae173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 06/25/2024] [Indexed: 11/28/2024] Open
Abstract
Eosinophils, traditionally associated as central innate effector cells with type 2 immunity during allergic and helminth parasitic diseases, have recently been revealed to have important roles in tissue homeostasis as well as host defense in a broader variety of infectious diseases. In a dedicated session at the 2023 biennial conference of the International Eosinophil Society titled "Eosinophils in Host Defense," the multifaceted roles eosinophils play against diverse pathogens, ranging from parasites to fungi, bacteria, and viruses, were presented. In this review, the session speakers offer a comprehensive summary of recent discoveries across pathogen classes, positioning eosinophils as pivotal leukocytes in both host defense and pathology. By unraveling the intricacies of eosinophil engagement in host resistance, this exploration may provide valuable insights not only to understand specific underpinnings of eosinophil functions related to each class of pathogens but also to develop novel therapeutics effective against a broad spectrum of infectious diseases.
Collapse
Affiliation(s)
- Pedro H Gazzinelli-Guimaraes
- Department of Microbiology, Immunology and Tropical Medicine, The George Washington School of Medicine and Health Sciences, 2300 I Street NW, Washington, DC 20037, United States
| | - Shelby M Jones
- Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, United States
| | - David Voehringer
- Department of Infection Biology, Universitätsklinikum Erlangen, Wasserturmstrasse 3-5, 91054 Erlangen, Germany
- FAU Profile Center Immunomedicine (FAU I-MED), Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Katrin D Mayer-Barber
- Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, Bethesda, MD 20892, United States
| | - Amali E Samarasinghe
- Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Children's Foundation Research Institute, 50 N Dunlap Street, Memphis, TN 38103, United States
| |
Collapse
|
3
|
Obeagu EI, Bluth MH. Eosinophils and Cognitive Impairment in Schizophrenia: A New Perspective. J Blood Med 2024; 15:227-237. [PMID: 38800637 PMCID: PMC11127652 DOI: 10.2147/jbm.s451988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 05/15/2024] [Indexed: 05/29/2024] Open
Abstract
Schizophrenia is a complex psychiatric disorder characterized by a wide array of cognitive impairments. While research has predominantly focused on the neurological aspects of schizophrenia, emerging evidence suggests that the immune system, specifically eosinophils, may play a significant role in the cognitive deficits associated with the disorder. This review presents a novel perspective on the interplay between eosinophils and cognitive impairment in schizophrenia. Eosinophils, traditionally associated with allergic responses and inflammation, have garnered limited attention within the realm of neuropsychiatry. Recent studies have hinted at a potential link between eosinophil activation and the pathogenesis of schizophrenia. In this comprehensive review, we delve into the world of eosinophils, elucidating their nature, functions, and interactions with the immune system. We examine the cognitive deficits observed in individuals with schizophrenia and discuss existing theories on the etiology of these impairments, focusing on immune system involvement. The paper also highlights the evolving body of research that supports the idea of eosinophilic influence on schizophrenia-related cognitive deficits. Furthermore, we explore potential mechanisms through which eosinophils may exert their effects on cognitive function in schizophrenia, including interactions with other immune cells and inflammatory pathways. By discussing the clinical implications and potential therapeutic avenues stemming from this newfound perspective, we underscore the practical significance of this emerging field of research. While this paper acknowledges the limitations and challenges inherent in studying eosinophils within the context of schizophrenia, it serves as a posit for novel thought in this vexing disease space as well as a call to action for future research endeavors. By providing a comprehensive survey of the existing literature and posing unanswered questions, we aim to inspire a reimagining of the relationship between eosinophils and cognitive impairment in schizophrenia, ultimately advancing our understanding and treatment of this debilitating disorder.
Collapse
Affiliation(s)
| | - Martin H Bluth
- Department of Pathology, Division of Blood Transfusion Medicine, Maimonides Medical Center, Brooklyn, NY, USA
| |
Collapse
|
4
|
Assogba YP, Adechina AP, Tchiakpe E, Nouatin OP, Kèkè RK, Bachabi M, Bankole HS, Yessoufou A. Advanced in immunological monitoring of HIV infection: profile of immune cells and cytokines in people living with HIV-1 in Benin. BMC Immunol 2024; 25:22. [PMID: 38643073 PMCID: PMC11031881 DOI: 10.1186/s12865-024-00615-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Accepted: 04/03/2024] [Indexed: 04/22/2024] Open
Abstract
BACKGROUND Immune cells and cytokines have been linked to viremia dynamic and immune status during HIV infection. They may serve as useful biomarkers in the monitoring of people living with HIV-1 (PLHIV-1). The present work was aimed to assess whether cytokines and immune cell profiles may help in the therapeutic follow-up of PLHIV-1. METHODS Forty PLHIV-1 in treatment success (PLHIV-1s) and fifty PLHIV-1 in treatment failure (PLHIV-1f) followed at the University Hospital of Abomey-Calavi/Sô-Ava in Benin were enrolled. Twenty healthy persons were also recruited as control group. Circulating cytokines and immune cells were quantified respectively by ELISA and flow cytometry. RESULTS PLHIV-1 exhibited low proportions of CD4 + T cells, NK, NKT, granulocytes, classical and non-classical monocytes, and high proportions of CD8 + T cells, particularly in the PLHIV-1f group, compared to control subjects. Eosinophils, neutrophils and B cell frequencies did not change between the study groups. Circulating IFN-γ decreased whereas IL-4 significantly increased in PLHIV-1s compared to PLHIV-1f and control subjects even though the HIV infection in PLHIV-1s downregulated the high Th1 phenotype observed in control subjects. However, Th1/Th2 ratio remained biased to a Th1 phenotype in PLHIV-1f, suggesting that high viral load may have maintained a potential pro-inflammatory status in these patients. Data on inflammatory cytokines showed that IL-6 and TNF-α concentrations were significantly higher in PLHIV-1s and PLHIV-1f groups than in control subjects. Significant high levels of IL-5 and IL-7 were observed in PLHIV-1f compared to controls whereas PLHIV-1s presented only a high level of IL-5. No change was observed in IL-13 levels between the study groups. CONCLUSION Our study shows that, in addition to CD4/CD8 T cell ratio, NK and NKT cells along with IL-6, TNF-α, IL-5 and IL-7 cytokines could serve as valuable immunological biomarkers in the therapeutic monitoring of PLHIV-1 although a larger number of patients would be necessary to confirm these results.
Collapse
Affiliation(s)
- Yaou Pierrot Assogba
- Laboratory of Cell Biology, Physiology and Immunology, Department of Biochemistry and Cellular Biology, Faculty of Sciences and Technology (FAST), Institute of Applied Biomedical Sciences (ISBA), University of Abomey-Calavi (UAC), Cotonou, 01 BP 526, Benin
| | - Adefounke Prudencia Adechina
- Laboratory of Cell Biology, Physiology and Immunology, Department of Biochemistry and Cellular Biology, Faculty of Sciences and Technology (FAST), Institute of Applied Biomedical Sciences (ISBA), University of Abomey-Calavi (UAC), Cotonou, 01 BP 526, Benin
| | - Edmond Tchiakpe
- Laboratory of Cell Biology, Physiology and Immunology, Department of Biochemistry and Cellular Biology, Faculty of Sciences and Technology (FAST), Institute of Applied Biomedical Sciences (ISBA), University of Abomey-Calavi (UAC), Cotonou, 01 BP 526, Benin
- National Reference Laboratory of Health Program Fighting Against AIDS in Benin (LNR/PSLS), Ministry of Health, Cotonou, BP 1258, Benin
| | | | - René K Kèkè
- National Reference Laboratory of Health Program Fighting Against AIDS in Benin (LNR/PSLS), Ministry of Health, Cotonou, BP 1258, Benin
| | - Moussa Bachabi
- National Reference Laboratory of Health Program Fighting Against AIDS in Benin (LNR/PSLS), Ministry of Health, Cotonou, BP 1258, Benin
| | - Honoré Sourou Bankole
- The Laboratory of Research and Applied Biology (LARBA), Unité de Recherche en Microbiologie Appliquée et Pharmacologie des Substances Naturelles, EPAC, Université d'Abomey-Calavi (UAC), Cotonou, 01 BP 2009, Bénin
| | - Akadiri Yessoufou
- Laboratory of Cell Biology, Physiology and Immunology, Department of Biochemistry and Cellular Biology, Faculty of Sciences and Technology (FAST), Institute of Applied Biomedical Sciences (ISBA), University of Abomey-Calavi (UAC), Cotonou, 01 BP 526, Benin.
- Centre de Recherche pour la lutte contre les Maladies Infectieuses Tropicales (CReMIT), Université d'Abomey-Calavi (UAC), Cotonou, 01 BP 526, Benin.
- Institute of Applied Biomedical Sciences (ISBA), Ministry of High Education and Scientific Research, Cotonou, 01 BP 918, Bénin.
| |
Collapse
|
5
|
Szymczyk A, Jaworski J, Podhorecka M. The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review. Cent Eur J Immunol 2024; 49:60-69. [PMID: 38812609 PMCID: PMC11130981 DOI: 10.5114/ceji.2024.136512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2019] [Accepted: 01/17/2024] [Indexed: 05/31/2024] Open
Abstract
Eosinophilia is a feature of multiple conditions, both hematologic and non-hematologic, and may be associated with organ damage. The pathogenesis of eosinophilia can follow two distinct pathways. Primary eosinophilia is caused by a cell-intrinsic mechanism originating from clonal expansion of eosinophils through acquisition of a somatic mutation, such as FIP1L1-PDGFRA. In recent years, great progress has been made in the field of pathogenesis and molecularly targeted therapy of neoplastic eosinophilia. The diagnostic procedure should include, among other things, morphologic analysis of blood and bone marrow samples, cytogenetics and fluorescence in situ-hybridization tests to detect evidence of an acute or chronic myeloid or lymphoid disorder. Secondary eosinophilia follows a cell-extrinsic mechanism as a response to exogenous cytokines. In most clinical cases, peripheral blood eosinophilia is reactive and typically associated with non-hematological disorders such as infections, allergic conditions, connective tissue disorders, vasculitis, malignancy, or endocrinopathies. Nonetheless, the cause of most cases of hypereosinophilic syndrome remains unknown. In this article, we present a short review focused on differential diagnosis of eosinophilia and eosinophilic disorders. The diagnosis of eosinophilia is a challenge for physicians; thus this review may be useful in clinical practice.
Collapse
Affiliation(s)
- Agnieszka Szymczyk
- Department of Hematology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland
| | | | - Monika Podhorecka
- Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland
| |
Collapse
|
6
|
Weaver MD, Glass B, Aplanalp C, Patel G, Mazhil J, Wang I, Dalia S. Review of Peripheral Blood Eosinophilia: Workup and Differential Diagnosis. HEMATO 2024; 5:81-108. [DOI: 10.3390/hemato5010008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2025]
Abstract
Eosinophils are a type of granulocyte key to immune system modulation seen in a number of disease processes. Nearly every major organ system can be connected to peripheral eosinophilia through a number of different disease processes, ranging from benign conditions to malignancy. In this paper, we review both common and rare causes of peripheral eosinophilia, their symptoms, and a framework for the workup of peripheral eosinophilia of unknown etiology.
Collapse
Affiliation(s)
- Michael Dennis Weaver
- Department of Graduate Medical Education, Freeman Health System, 1102 W, 32nd Street, Joplin, MO 64804, USA
| | - Bianca Glass
- College of Osteopathic Medicine, Kansas City University, 2901 St Johns Blvd, Joplin, MO 64804, USA
| | - Chance Aplanalp
- College of Osteopathic Medicine, Kansas City University, 2901 St Johns Blvd, Joplin, MO 64804, USA
| | - Gauri Patel
- College of Osteopathic Medicine, Kansas City University, 2901 St Johns Blvd, Joplin, MO 64804, USA
| | - Jeshrine Mazhil
- College of Osteopathic Medicine, Kansas City University, 2901 St Johns Blvd, Joplin, MO 64804, USA
| | - Isabella Wang
- College of Osteopathic Medicine, Kansas City University, 2901 St Johns Blvd, Joplin, MO 64804, USA
| | - Samir Dalia
- Department of Hematology and Oncology, Mercy Health System, 100 Mercy Way, Joplin, MO 64804, USA
| |
Collapse
|
7
|
Eiros R, Barreiro-Pérez M, Martín-García A, Almeida J, Villacorta E, Pérez-Pons A, Merchán S, Torres-Valle A, Sánchez-Pablo C, González-Calle D, Pérez-Escurza O, Toranzo I, Díaz-Peláez E, Fuentes-Herrero B, Macías-Álvarez L, Oliva-Ariza G, Lecrevisse Q, Fluxa R, Bravo-Grande JL, Orfao A, Sánchez PL. [Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers]. Rev Esp Cardiol 2022; 75:735-747. [PMID: 35039707 PMCID: PMC8755423 DOI: 10.1016/j.recesp.2021.10.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Accepted: 10/22/2021] [Indexed: 11/24/2022]
Abstract
Introduction and objectives The cardiac sequelae of SARS-CoV-2 infection are still poorly documented. We conducted a cross-sectional study in healthcare workers to report evidence of pericardial and myocardial involvement after SARS-CoV-2 infection. Methods We studied 139 healthcare workers with confirmed past SARS-CoV-2 infection. Participants underwent clinical assessment, electrocardiography, and laboratory tests, including immune cell profiling and cardiac magnetic resonance (CMR). Clinically suspected pericarditis was diagnosed when classic criteria were present and clinically suspected myocarditis was based on the combination of at least 2 CMR criteria. Results Median age was 52 (41-57) years, 71.9% were women, and 16.5% were previously hospitalized for COVID-19 pneumonia. On examination (10.4 [9.3-11.0] weeks after infection-like symptoms), participants showed hemodynamic stability. Chest pain, dyspnea or palpitations were present in 41.7% participants, electrocardiographic abnormalities in 49.6%, NT-proBNP elevation in 7.9%, troponin in 0.7%, and CMR abnormalities in 60.4%. A total of 30.9% participants met criteria for either pericarditis and/or myocarditis: isolated pericarditis was diagnosed in 5.8%, myopericarditis in 7.9%, and isolated myocarditis in 17.3%. Most participants (73.2%) showed altered immune cell counts in blood, particularly decreased eosinophil (27.3%; P < .001) and increased cytotoxic T cell numbers (17.3%; P < .001). Clinically suspected pericarditis was associated (P < .005) with particularly elevated cytotoxic T cells and decreased eosinophil counts, while participants diagnosed with clinically suspected myopericarditis or myocarditis had lower (P < .05) neutrophil counts, natural killer-cells, and plasma cells. Conclusions Pericardial and myocardial involvement with clinical stability are frequent after SARS-CoV-2 infection and are associated with specific immune cell profiles.Full English text available from:www.revespcardiol.org/en.
Collapse
Affiliation(s)
- Rocío Eiros
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - Manuel Barreiro-Pérez
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - Ana Martín-García
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Facultad de Medicina, Universidad de Salamanca, Salamanca, España
| | - Julia Almeida
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Facultad de Medicina, Universidad de Salamanca, Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - Eduardo Villacorta
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Facultad de Medicina, Universidad de Salamanca, Salamanca, España
| | - Alba Pérez-Pons
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - Soraya Merchán
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - Alba Torres-Valle
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - Clara Sánchez-Pablo
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - David González-Calle
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - Oihane Pérez-Escurza
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - Inés Toranzo
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - Elena Díaz-Peláez
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - Blanca Fuentes-Herrero
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - Laura Macías-Álvarez
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - Guillermo Oliva-Ariza
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - Quentin Lecrevisse
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - Rafael Fluxa
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Facultad de Medicina, Universidad de Salamanca, Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - José L Bravo-Grande
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Servicio de Prevención de Riesgos Laborales, Hospital Universitario de Salamanca, Salamanca, España
| | - Alberto Orfao
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Facultad de Medicina, Universidad de Salamanca, Salamanca, España
- Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, España
- Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, España
| | - Pedro L Sánchez
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, España
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), España
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
- Facultad de Medicina, Universidad de Salamanca, Salamanca, España
| |
Collapse
|
8
|
Eiros R, Barreiro-Pérez M, Martín-García A, Almeida J, Villacorta E, Pérez-Pons A, Merchán S, Torres-Valle A, Sánchez-Pablo C, González-Calle D, Pérez-Escurza O, Toranzo I, Díaz-Peláez E, Fuentes-Herrero B, Macías-Álvarez L, Oliva-Ariza G, Lecrevisse Q, Fluxa R, Bravo-Grande JL, Orfao A, Sánchez PL. Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers. REVISTA ESPANOLA DE CARDIOLOGIA (ENGLISH ED.) 2022; 75:734-746. [PMID: 34866030 PMCID: PMC8570413 DOI: 10.1016/j.rec.2021.11.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Accepted: 10/22/2021] [Indexed: 12/14/2022]
Abstract
INTRODUCTION AND OBJECTIVES The cardiac sequelae of SARS-CoV-2 infection are still poorly documented. We conducted a cross-sectional study in healthcare workers to report evidence of pericardial and myocardial involvement after SARS-CoV-2 infection. METHODS We studied 139 healthcare workers with confirmed past SARS-CoV-2 infection. Participants underwent clinical assessment, electrocardiography, and laboratory tests, including immune cell profiling and cardiac magnetic resonance (CMR). Clinically suspected pericarditis was diagnosed when classic criteria were present and clinically suspected myocarditis was based on the combination of at least 2 CMR criteria. RESULTS Median age was 52 (41-57) years, 71.9% were women, and 16.5% were previously hospitalized for COVID-19 pneumonia. On examination (10.4 [9.3-11.0] weeks after infection-like symptoms), participants showed hemodynamic stability. Chest pain, dyspnea or palpitations were present in 41.7% participants, electrocardiographic abnormalities in 49.6%, NT-proBNP elevation in 7.9%, troponin in 0.7%, and CMR abnormalities in 60.4%. A total of 30.9% participants met criteria for either pericarditis and/or myocarditis: isolated pericarditis was diagnosed in 5.8%, myopericarditis in 7.9%, and isolated myocarditis in 17.3%. Most participants (73.2%) showed altered immune cell counts in blood, particularly decreased eosinophil (27.3%; P<.001) and increased cytotoxic T cell numbers (17.3%; P <.001). Clinically suspected pericarditis was associated (P <.005) with particularly elevated cytotoxic T cells and decreased eosinophil counts, while participants diagnosed with clinically suspected myopericarditis or myocarditis had lower (P <.05) neutrophil counts, natural killer-cells, and plasma cells. CONCLUSIONS Pericardial and myocardial involvement with clinical stability are frequent after SARS-CoV-2 infection and are associated with specific immune cell profiles.
Collapse
Affiliation(s)
- Rocío Eiros
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - Manuel Barreiro-Pérez
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - Ana Martín-García
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Julia Almeida
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Eduardo Villacorta
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Alba Pérez-Pons
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Soraya Merchán
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - Alba Torres-Valle
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Clara Sánchez-Pablo
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - David González-Calle
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - Oihane Pérez-Escurza
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Inés Toranzo
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - Elena Díaz-Peláez
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - Blanca Fuentes-Herrero
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Laura Macías-Álvarez
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - Guillermo Oliva-Ariza
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Quentin Lecrevisse
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Rafael Fluxa
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - José L Bravo-Grande
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Servicio de Prevención de Riesgos Laborales, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Alberto Orfao
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain; Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain; Servicio de Citometría, Nucleus - Universidad de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Pedro L Sánchez
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain.
| |
Collapse
|
9
|
Iordanov RB, Leining LM, Wu M, Chan G, DiNardo AR, Mejia R. Case Report: Molecular Diagnosis of Cystoisospora belli in a Severely Immunocompromised Patient with HIV and Kaposi Sarcoma. Am J Trop Med Hyg 2022; 106:678-680. [PMID: 34844211 PMCID: PMC8832916 DOI: 10.4269/ajtmh.21-0289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 10/06/2021] [Indexed: 02/03/2023] Open
Abstract
Diarrhea in an immunocompromised patient has a broad infectious differential. Diagnosis is difficult despite advances in diagnostic modalities. We report a case of a 45-year-old Nigerian woman who immigrated to the United States 2 years ago. She presented to the hospital with gastrointestinal bleeding, newly diagnosed HIV, and disseminated Kaposi sarcoma. During hospitalization, the patient had an onset of watery diarrhea and high eosinophilia. Subsequent stool analysis using multi-parallel real-time quantitative polymerase chain reaction for 13 parasites was positive for Cystoisospora belli. The patient was treated with trimethoprim-sulfamethoxazole, but had relapsed disease when her antibiotics were stopped prematurely. After restarting trimethoprim-sulfamethoxazole, her diarrhea and eosinophilia improved, and she had undetectable Cystoisospora belli DNA on repeat stool quantitative polymerase chain reaction. This case highlights the importance of a thorough workup for diarrhea, including parasites, especially for immunocompromised patients. Antibiotic prophylaxis is recommended in patients with Cystoisospora belli and HIV/AIDS.
Collapse
Affiliation(s)
- Roumen Borilov Iordanov
- Infectious Diseases Section, Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Lauren M. Leining
- Laboratory of Human Parasitology, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas
| | - Meng Wu
- Rheumatology & Infectious Diseases, PLLC, Houston, Texas
| | - Galant Chan
- Infectious Diseases Section, Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Andrew R. DiNardo
- Infectious Diseases Section, Department of Medicine, Baylor College of Medicine, Houston, Texas
| | - Rojelio Mejia
- Laboratory of Human Parasitology, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas;,Address corresponding to Rojelio Mejia, Baylor College of Medicine, One Baylor Plaza, BCM 113, Houston, TX 77030. E-mail:
| |
Collapse
|
10
|
Tong X, Cheng A, Yuan X, Zhong X, Wang H, Zhou W, Xu X, Li Y. Characteristics of peripheral white blood cells in COVID-19 patients revealed by a retrospective cohort study. BMC Infect Dis 2021; 21:1236. [PMID: 34886793 PMCID: PMC8655490 DOI: 10.1186/s12879-021-06899-7] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Accepted: 11/16/2021] [Indexed: 01/12/2023] Open
Abstract
Background Peripheral hematological changes in severe COVID-19 patients may reflect the immune response during SARS-CoV-2 infection. Characteristics of peripheral white blood cells as early signals were needed to be investigated for clarifying its associations with the fatal outcomes in COVID-19 patients. Methods A retrospective cohort study was performed and the hospitalized COVID-19 patients were recruited in wards of Sino-French New City Branch of Tongji Hospital in Wuhan, Hubei province, China. Characteristics of peripheral white blood cells in survivors and non-survivors were analyzed. Comparison among patients with different level of eosinophils was performed. Results Of 198 patients included in this study, 185 were discharged and 13 died. Levels of eosinophils, lymphocytes and basophils in non-survivors were significantly lower than those in survivors. Death rate in low eosinophils group was higher and no patient died in normal eosinophils group (16.7% vs 0, P < 0.001). The proportion of patients in low eosinophils group who used glucocorticoids was higher than in normal eosinophils group, but glucocorticoids usage was not an indicator for death in subgroup analysis in low eosinophils patients. Moreover, positive correlation was found between the counts of lymphocytes and eosinophils in patients with glucocorticoids use but not in patients without the treatment. Conclusions Hematological changes differed between survivors and non-survivors with COVID-19. Lymphopenia and eosinopenia could be predictors for poor prognosis of COVID-19 patients. Initial counts of eosinophils may guide us in usage of glucocorticoids for COVID-19 treatment. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-06899-7.
Collapse
Affiliation(s)
- Xunliang Tong
- Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Anqi Cheng
- Tobacco Medicine and Tobacco Cessation Center, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.,WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention, Beijing, China.,National Clinical Research Center for Respiratory Diseases, Beijing, China.,Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Xueting Yuan
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Xuefeng Zhong
- Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - He Wang
- Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Wei Zhou
- Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Xiaomao Xu
- Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
| | - Yanming Li
- Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
| |
Collapse
|
11
|
Folci M, Ramponi G, Arcari I, Zumbo A, Brunetta E. Eosinophils as Major Player in Type 2 Inflammation: Autoimmunity and Beyond. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2021; 1347:197-219. [PMID: 34031864 DOI: 10.1007/5584_2021_640] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
Eosinophils are a subset of differentiated granulocytes which circulate in peripheral blood and home in several body tissues. Along with their traditional relevance in helminth immunity and allergy, eosinophils have been progressively attributed important roles in a number of homeostatic and pathologic situations. This review aims at summarizing available evidence about eosinophils functions in homeostasis, infections, allergic and autoimmune disorders, and solid and hematological cancers.Their structural and biological features have been described, along with their physiological behavior. This includes their chemokines, cytokines, granular contents, and extracellular traps. Besides, pathogenic- and eosinophilic-mediated disorders have also been addressed, with the aim of highlighting their role in Th2-driven inflammation. In allergy, eosinophils are implicated in the pathogenesis of atopic dermatitis, allergic rhinitis, and asthma. They are also fundamentally involved in autoimmune disorders such as eosinophilic esophagitis, eosinophilic gastroenteritis, acute and chronic eosinophilic pneumonia, and eosinophilic granulomatosis with polyangiitis. In infections, eosinophils are involved in protection not only from parasites but also from fungi, viruses, and bacteria. In solid cancers, local eosinophilic infiltration is variably associated with an improved or worsened prognosis, depending on the histotype. In hematologic neoplasms, eosinophilia can be the consequence of a dysregulated cytokine production or the result of mutations affecting the myeloid lineage.Recent experimental evidence was thoroughly reviewed, with findings which elicit a complex role for eosinophils, in a tight balance between host defense and tissue damage. Eventually, emerging evidence about eosinophils in COVID-19 infection was also discussed.
Collapse
Affiliation(s)
- Marco Folci
- Humanitas Clinical and Research Center - IRCCS, Milan, Italy. .,Department of Biomedical Sciences, Humanitas University, Milan, Italy.
| | - Giacomo Ramponi
- Humanitas Clinical and Research Center - IRCCS, Milan, Italy
| | - Ivan Arcari
- Humanitas Clinical and Research Center - IRCCS, Milan, Italy
| | - Aurora Zumbo
- Humanitas Clinical and Research Center - IRCCS, Milan, Italy
| | - Enrico Brunetta
- Humanitas Clinical and Research Center - IRCCS, Milan, Italy.,Department of Biomedical Sciences, Humanitas University, Milan, Italy
| |
Collapse
|
12
|
Reguero-Del Cura L, Pérez-Paredes MG, Cortés-Vázquez MA, López-Sundh AE, González-Vela MC, Gómez-Fernández C, González-López MA. Secondary hypereosinophilic syndrome: an unusual manifestation in a patient with syringotropic mycosis fungoides and human immunodeficiency virus infection. Australas J Dermatol 2021; 62:213-216. [PMID: 33421095 DOI: 10.1111/ajd.13531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 11/03/2020] [Accepted: 11/15/2020] [Indexed: 11/26/2022]
Abstract
Syringotropic mycosis fungoides is a very rare variant of cutaneous T-cell lymphomas characterised by prominent involvement of the eccrine glands. Hypereosinophilic syndrome refers to a rare group of conditions that are associated with persistent eosinophilia with organ involvement. It is classified into idiopathic, primary and secondary (reactive). We report herein an unusual case of hypereosinophilic syndrome with great impact on morbidity, which developed in a patient with human immunodeficiency virus infection and long-time misdiagnosed syringotropic mycosis fungoides.
Collapse
Affiliation(s)
- Leandra Reguero-Del Cura
- Divisions of, Division of, Dermatology, University Hospital Marqués de Valdecilla (U.H.M.V), Santander, Spain
| | - María Genma Pérez-Paredes
- Divisions of, Division of, Dermatology, University Hospital Marqués de Valdecilla (U.H.M.V), Santander, Spain
| | | | - Ana Elisabet López-Sundh
- Divisions of, Division of, Dermatology, University Hospital Marqués de Valdecilla (U.H.M.V), Santander, Spain
| | | | - Cristina Gómez-Fernández
- Divisions of, Division of, Dermatology, University Hospital Marqués de Valdecilla (U.H.M.V), Santander, Spain
| | | |
Collapse
|
13
|
O'Donovan SM, Eby H, Henkel ND, Creeden J, Imami A, Asah S, Zhang X, Wu X, Alnafisah R, Taylor RT, Reigle J, Thorman A, Shamsaei B, Meller J, McCullumsmith RE. Identification of new drug treatments to combat COVID19: A signature-based approach using iLINCS. RESEARCH SQUARE 2020:rs.3.rs-25643. [PMID: 32702077 PMCID: PMC7336712 DOI: 10.21203/rs.3.rs-25643/v1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The COVID-19 pandemic caused by the novel SARS-CoV-2 is more contagious than other coronaviruses and has higher rates of mortality than influenza. As no vaccine or drugs are currently approved to specifically treat COVID-19, identification of effective therapeutics is crucial to treat the afflicted and limit disease spread. We deployed a bioinformatics workflow to identify candidate drugs for the treatment of COVID-19. Using an "omics" repository, the Library of Integrated Network-Based Cellular Signatures (LINCS), we simultaneously probed transcriptomic signatures of putative COVID-19 drugs and signatures of coronavirus-infected cell lines to identify therapeutics with concordant signatures and discordant signatures, respectively. Our findings include three FDA approved drugs that have established antiviral activity, including protein kinase inhibitors, providing a promising new category of candidates for COVID-19 interventions.
Collapse
|
14
|
Curto E, Torrego A, Garin N, Crespo-Lessmann A, Plaza V. HIV-infected patient with severe asthma treated with mepolizumab: Case report. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE 2020; 8:2414-2416. [PMID: 32272285 DOI: 10.1016/j.jaip.2020.03.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 03/09/2020] [Accepted: 03/16/2020] [Indexed: 01/17/2023]
Affiliation(s)
- Elena Curto
- Department of Respiratory Medicine and Allergology, Hospital de la Santa Creu i Sant Pau, Institute of Sant Pau Biomedical Research, Universitat Autònoma de Barcelona, Barcelona, Spain.
| | - Alfons Torrego
- Department of Respiratory Medicine and Allergology, Hospital de la Santa Creu i Sant Pau, Institute of Sant Pau Biomedical Research, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Noe Garin
- Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Astrid Crespo-Lessmann
- Department of Respiratory Medicine and Allergology, Hospital de la Santa Creu i Sant Pau, Institute of Sant Pau Biomedical Research, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Vicente Plaza
- Department of Respiratory Medicine and Allergology, Hospital de la Santa Creu i Sant Pau, Institute of Sant Pau Biomedical Research, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
15
|
McLellan J, Gill MJ, Vaughan S, Meatherall B. Schistosoma and Strongyloides screening in migrants initiating HIV Care in Canada: a cross sectional study. BMC Infect Dis 2020; 20:76. [PMID: 31992216 PMCID: PMC6986152 DOI: 10.1186/s12879-020-4779-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Accepted: 01/08/2020] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Following migration from Schistosoma and Strongyloides endemic to non-endemic regions, people remain at high risk for adverse sequelae from these chronic infections. HIV co-infected persons are particularly vulnerable to the serious and potentially fatal consequences of untreated helminth infection. While general screening guidelines exist for parasitic infection screening in immigrant populations, they remain silent on HIV positive populations. This study assessed the seroprevalence, epidemiology and laboratory characteristics of these two parasitic infections in a non-endemic setting in an immigrant/refugee HIV positive community. METHODS Between February 2015 and 2018 individuals born outside of Canada receiving care at the centralized HIV clinic serving southern Alberta, Canada were screened by serology and direct stool analysis for schistosomiasis and strongyloidiasis. Canadian born persons with travel-based exposure risk factors were also screened. Epidemiologic and laboratory values were analyzed using bivariate logistic regression. We assessed the screening utility of serology, direct stool analysis, eosinophilia and hematuria. RESULTS 253 HIV positive participants were screened. The prevalence of positive serology for Schistosoma and Strongyloides was 19.9 and 4.4%, respectively. Age between 40 and 50 years (OR 2.50, 95% CI 1.13-5.50), refugee status (3.55, 1.72-7.33), country of origin within Africa (6.15, 2.44-18.60), eosinophilia (3.56, 1.25-10.16) and CD4 count < 200 cells/mm3 (2.46, 1.02-5.92) were associated with positive Schistosoma serology. Eosinophilia (11.31, 2.03-58.94) was associated with positive Strongyloides serology. No Schistosoma or Strongyloides parasites were identified by direct stool microscopy. Eosinophilia had poor sensitivity for identification of positive serology. Hematuria was not associated with positive Schistosoma serology. CONCLUSION Positive Schistosoma and Strongyloides serology was common in this migrant HIV positive population receiving HIV care in Southern Alberta. This supports the value of routine parasitic screening as part of standard HIV care in non-endemic areas. Given the high morbidity and mortality in this relatively immunosuppressed population, especially for Strongyloides infection, screening should include both serologic and direct parasitological tests. Eosinophilia and hematuria should not be used for Schistosoma and Strongyloides serologic screening in HIV positive migrants in non-endemic settings.
Collapse
Affiliation(s)
- Jessica McLellan
- Department of Medicine, The University of Calgary, Calgary, Alberta, Canada.
| | - M John Gill
- Department of Medicine, The University of Calgary, Calgary, Alberta, Canada
- Division of Infectious Disease, The University of Calgary, Calgary, Alberta, Canada
| | - Stephen Vaughan
- Department of Medicine, The University of Calgary, Calgary, Alberta, Canada
- Division of Infectious Disease, The University of Calgary, Calgary, Alberta, Canada
| | - Bonnie Meatherall
- Department of Medicine, The University of Calgary, Calgary, Alberta, Canada
- Division of Infectious Disease, The University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
16
|
Eosinophils, Lymphocytes, and Myocytes, Oh My: HIV-Associated Myocarditis. Am J Med 2020; 133:52-55. [PMID: 31251904 DOI: 10.1016/j.amjmed.2019.05.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 05/10/2019] [Accepted: 05/12/2019] [Indexed: 11/21/2022]
|
17
|
Abstract
Physicians may encounter blood or tissue eosinophilia through a routine complete blood count with differential or a tissue pathology report. In this article, the basic biology of eosinophils is reviewed and definitions of blood eosinophilia, as well as the challenges of defining tissue eosinophilia, are discussed. Conditions associated with eosinophilia are briefly discussed as well as a general approach to evaluating eosinophilia. Future challenges include determining which eosinophil-associated diseases benefit from eosinophil-targeted therapy and identifying biomarkers for disease activity and diagnosis.
Collapse
Affiliation(s)
- Fei Li Kuang
- Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, 4 Memorial Drive, B1-27, Bethesda, MD 20892, USA.
| |
Collapse
|
18
|
Rising Eosinophilia After a Trip to the Caribbean in an HIV-Infected Man. INFECTIOUS DISEASES IN CLINICAL PRACTICE 2020. [DOI: 10.1097/ipc.0000000000000805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Gauckler P, Shin JI, Mayer G, Kronbichler A. Eosinophilia and Kidney Disease: More than Just an Incidental Finding? J Clin Med 2018; 7:E529. [PMID: 30544782 PMCID: PMC6306805 DOI: 10.3390/jcm7120529] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 11/29/2018] [Accepted: 12/05/2018] [Indexed: 02/07/2023] Open
Abstract
Peripheral blood eosinophilia (PBE), defined as 500 eosinophils or above per microliter (µL) blood, is a condition that is not uncommon but often neglected in the management of patients with chronic kidney disease (CKD), acute kidney injury (AKI), or patients on renal replacement therapy (RRT). The nature of PBE in the context of kidney diseases is predominantly secondary or reactive and has to be distinguished from primary eosinophilic disorders. Nonetheless, the finding of persistent PBE can be a useful clue for the differential diagnosis of underdiagnosed entities and overlapping syndromes, such as eosinophilic granulomatosis with polyangiitis (EGPA), IgG4-related disease (IgG4-RD), acute interstitial nephritis (AIN), or the hypereosinophilic syndrome (HES). For patients on RRT, PBE may be an indicator for bio-incompatibility of the dialysis material, acute allograft rejection, or Strongyloides hyperinfection. In a subset of patients with EGPA, eosinophils might even be the driving force in disease pathogenesis. This improved understanding is already being used to facilitate novel therapeutic options. Mepolizumab has been licensed for the management of EGPA and is applied with the aim to abrogate the underlying immunologic process by blocking interleukin-5. The current article provides an overview of different renal pathologies that are associated with PBE. Further scientific effort is required to understand the exact role and function of eosinophils in these disorders which may pave the way to improved interdisciplinary management of such patients.
Collapse
Affiliation(s)
- Philipp Gauckler
- Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria.
| | - Jae Il Shin
- Department of Pediatrics, Yonsei University College of Medicine, Seoul 03722, Korea.
- Department of Pediatric Nephrology, Severance Children's Hospital, Seoul 03722, Korea.
- Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul 03722, Korea.
- Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30322, USA.
| | - Gert Mayer
- Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria.
| | - Andreas Kronbichler
- Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria.
| |
Collapse
|
20
|
Gupta P, Dua R, Bhatia M, Gupta PK, Kaistha N. Eosinophilia in Advanced HIV Infection with Hyperinfection Syndrome: A Case Report. JOURNAL OF PHARMACY AND BIOALLIED SCIENCES 2018; 10:102-105. [PMID: 29962800 PMCID: PMC5998694 DOI: 10.4103/jpbs.jpbs_217_17] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Strongyloides stercoralis is a soil-transmitted helminth that occurs almost worldwide, yet estimates about its prevalence are not well documented. The spectrum of clinical manifestations of strongyloidiasis is wide, ranging from asymptomatic disease to hyperinfection or dissemination of larvae involving multiple organ systems. Immunosuppression can increase the risk of hyperinfection syndrome in patients with strongyloidiasis. Strongyloidiasis continues to remain a neglected tropical disease, the diagnosis of which is often overlooked by clinicians and diagnosticians alike. The paucity of published literature from India further accentuates this problem. We hereby present a case report with the aim of elucidating this relatively underreported infection.
Collapse
Affiliation(s)
- Pratima Gupta
- Department of Microbiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
| | - Ruchi Dua
- Department of Pulmonary Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand-249203, India
| | - Mohit Bhatia
- Department of Microbiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
| | - Puneet K Gupta
- Department of Microbiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
| | - Neelam Kaistha
- Department of Microbiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
| |
Collapse
|
21
|
Eosinophils from Physiology to Disease: A Comprehensive Review. BIOMED RESEARCH INTERNATIONAL 2018; 2018:9095275. [PMID: 29619379 PMCID: PMC5829361 DOI: 10.1155/2018/9095275] [Citation(s) in RCA: 171] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Accepted: 12/27/2017] [Indexed: 12/26/2022]
Abstract
Despite being the second least represented granulocyte subpopulation in the circulating blood, eosinophils are receiving a growing interest from the scientific community, due to their complex pathophysiological role in a broad range of local and systemic inflammatory diseases as well as in cancer and thrombosis. Eosinophils are crucial for the control of parasitic infections, but increasing evidence suggests that they are also involved in vital defensive tasks against bacterial and viral pathogens including HIV. On the other side of the coin, eosinophil potential to provide a strong defensive response against invading microbes through the release of a large array of compounds can prove toxic to the host tissues and dysregulate haemostasis. Increasing knowledge of eosinophil biological behaviour is leading to major changes in established paradigms for the classification and diagnosis of several allergic and autoimmune diseases and has paved the way to a "golden age" of eosinophil-targeted agents. In this review, we provide a comprehensive update on the pathophysiological role of eosinophils in host defence, inflammation, and cancer and discuss potential clinical implications in light of recent therapeutic advances.
Collapse
|
22
|
Goussard P, Gie RP. HIV-related chronic lung disease in adolescents: are we prepared for the future? Expert Rev Respir Med 2017; 11:969-975. [PMID: 28956954 DOI: 10.1080/17476348.2017.1386562] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
INTRODUCTION Chronic lung diseases (CLD) are the most chronic disease occurring in adolescents living with human immunodeficiency virus (ALHIV). In ALHIV who received antiretroviral therapy (ART) late in childhood, bronchiectasis, bronchiolitis obliterans and interstitial pneumonitis are common. In adolescents who received ART early in life the spectrum of CLD has changed with asthma and chronic obstructive pulmonary disease being common. Areas covered: The aim of this paper was to review CLD in ALHIV. We conducted a literature review of electronic databases focusing on CLD that were common prior to the introduction of ART (1996-2004), the present situation where ART is widely available (2005 to 2016), and articles which aided us speculating on the impact of HIV-related CLD in adolescents transitioning to adult HIV-clinics. Amongst the approximately 2.1 million adolescents living with HIV, CLD commonly occurs. Awareness of the CLD amongst ALHIV needs to be raised to ensure that disease appropriate treatment is available to these vulnerable adolescents. Expert commentary: As adolescents' transition from pediatric HIV-clinics to adult HIV-clinics the evidence shows that adolescents might not receive optimal care if adult pulmonologists are not aware of the CLD that commonly occur in ALHIV.
Collapse
Affiliation(s)
- Pierre Goussard
- a Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences , Stellenbosch University , Cape Town , South Africa
| | - Robert P Gie
- a Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences , Stellenbosch University , Cape Town , South Africa
| |
Collapse
|